On April 23, 2026, the FDA granted accelerated approval to Otarmeni™ (lunsotogene parvec‑cwha) from Regeneron Pharmaceuticals – the first FDA‑approved gene therapy for patients with severe‑to‑profound sensorineural hearing loss caused by biallelic OTOF gene variants.
This one‑time, intracochlear gene therapy represents a potentially disease‑modifying option for an ultra‑rare condition where treatment historically relied on hearing devices or cochlear implantation. In the pivotal CHORD phase I/II studies, 80% of patients met the primary endpoint for hearing improvement at 24 weeks, and 42% achieved normal‑hearing thresholds, including the ability to hear whispers. Regeneron has announced it will provide Otarmeni at no cost to clinically eligible patients in the U.S., though administration costs may still apply.
The product will be excluded at launch from the ProAct Advantage formulary while the formulary placement review process is completed.
This approval underscores the accelerating pace of gene therapy innovation, the evolving role of value and evidence assessment, and the importance of thoughtful coverage strategies as transformative—but complex—therapies enter the market.
